Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study will assess of the efficacy and safety of a once-daily, 50µg inhalation of NVA237
in moderate to severe chronic obstructive pulmonary disease (COPD) patients over 26 weeks
treatment.